1
Patient
Comprehensive profile
& risk assessment
AI-POWERED DEMENTIA INSIGHT
Proteomic AI for earlier dementia risk insight.
Centia Bio is developing AI-powered proteomic tools to estimate future dementia risk and reveal the biological pathways driving that risk.
Built at the intersection of proteomics, neurodegeneration, machine learning, and clinical informatics.
UNCERTAIN FUTURE
HEALTHIER FUTURE
Predict.
Personalize.
Prevent.
Turning patient proteomic data into personalized actionable insights for dementia prevention and treatment.
Identify risk earlier
with deep proteomic insights
Deep characterization
and monitoring of brain health with AI-powered analytics
Personalize prevention
for better brain health and longer, healthier lives
Centia Bio
Centia Bio is a proteomics and AI company pioneering the future of
dementia risk prediction and
personalized prevention.
The Problem
Dementia is often detected after years of silent biological change. By the time symptoms appear, many underlying molecular pathways may already be altered.
Current risk tools can help identify some at-risk individuals, but they often provide limited insight into why risk is elevated or which biological systems are contributing.
55M
people living with dementia worldwide
40%
of cases preventable with early, personalised intervention
50%
go undiagnosed - missed prevention windows
Risk is detected too late
Many individuals are identified only after measurable cognitive decline has already begun.
Research needs better stratification
Prevention studies and clinical research need better tools to identify who is at risk, when risk may emerge, and what biology may be driving that risk.
Biology is hard to interpret
Dementia risk reflects many interacting systems, including inflammation, vascular biology, metabolism, immune signaling, and neurodegeneration.
Our Solution
Centia Bio combines large-scale proteomic data with machine learning models trained on longitudinal aging and neurodegeneration datasets. Our platform is designed to generate time-specific dementia risk estimates and pathway-level interpretation from thousands of circulating proteins.
Personalised Medicine
2
Blood Proteome
7,000+ proteins
Deep proteomic profiling captures
the molecular fingerprint of risk.
3
AI Risk Engine
Multi-omic integration
Pathway enrichment
Risk prediction
Trajectory modelling
AI identifies dominant pathways
and predicts future risk.
4
Personalised Plan
Right treatment, Right time.
Lifestyle and behavioral intervention
Evidence-based lifestyle
changes to reduce risk.
Pharmacological intervention
Evidence-based lifestyle
changes to reduce risk.
Optimized intervention combinations
Integrated strategies tailored
to your unique biology.
ROADMAP
01
NOW
Dementia Risk Research
Time-specific risk prediction for cognitively normal and MCI populations.
02
Next
MCI Progression
Risk models to support research into progression from mild cognitive impairment to dementia.
03
Then
Pathway Attribution
Biological interpretation of risk across molecular pathways and organ systems.
04
Future
Trial Enrichment
Tools to help identify participants most likely to benefit from prevention studies.
05
Long Term
Clinical Decision Support
Validated tools to support personalized prevention and brain health planning.
TEAM
Built by operators and scientists.
MRI and medical imaging experts from the University of Minnesota, Vanderbilt, MGH, and the University of São Paulo. Advisors from Stanford and the broader MRI research community.
Ahmed Naguib, MS
CEO
Over a decade of experience in bioinformatics, clinical informatics, and healthcare commercialization. In leadership roles at Exact Sciences, Illumina, Becton Dickinson, and BioNano Genomics, he built scalable, compliant platforms for oncology, diagnostics, sequencing, and medication management — supporting regulated clinical workflows, real-world evidence generation, and go-to-market strategy.
Hamilton Oh, PhD
CSO
Expertise in proteomics, machine learning, aging, and neurodegenerative disease. BS from UCLA and PhD from Stanford University, trained in Dr. Tony Wyss-Coray’s laboratory — instrumental in developing proteomic tools to measure organ-specific aging and identify protein signatures of disease risk, healthspan, and longevity.
Contact with Us Now
Let’s collaborate with us!
Read and update the latest news from us. done eu magna quis felis.
The Centia Bio Process
STEP 1
Order
−
STEP 2
Collection
+
STEP 3
Lab
+
STEP 4
Results
+
STEP 5
Consultation
+
Order
The Centia test is ordered by your healthcare provider. We'll handle the rest.
Collection
A simple blood draw is all that's needed. The sample is shipped securely to our lab.
Lab
We measure over 7,000 proteins using advanced proteomics technology.
Results
Our AI platform analyzes your proteome to generate a clear risk profile.
Consultation
Your provider reviews your results and creates a personalized prevention plan.
Our mission: to transform dementia from an inevitable outcome into a preventable one.
Identify risk earlier
Enable personalized prevention
Improve brain health and lives
The Centia Bio Process
STEP 1
Order
−
Order
The Centia test is ordered by your healthcare provider. We'll handle the rest.
STEP 2
Collection
+
Collection
A simple blood draw is all that's needed. The sample is shipped securely to our lab.
STEP 3
Lab
+
Lab
We measure over 7,000 proteins using advanced proteomics technology.
STEP 4
Results
+
Results
Our AI platform analyzes your proteome to generate a clear risk profile.
STEP 5
Consultation
+
Consultation
Your provider reviews your results and creates a personalized prevention plan.
Our mission: to transform dementia from an inevitable outcome into a preventable one.
Identify risk earlier
Enable personalized prevention
Improve brain health and lives